PMID- 28529600
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220331
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 13
IP  - 5
DP  - 2017 May
TI  - Prospective evaluation of fluorescence in situ hybridization for diagnosing 
      urothelial carcinoma.
PG  - 3928-3934
LID - 10.3892/ol.2017.5926 [doi]
AB  - Urothelial carcinoma (UC) is the most common type of cancer of the bladder and 
      upper urinary tract, and is characterized by a high risk of recurrence and 
      progression. Urine fluorescence in situ hybridization (FISH) is a technique that 
      detects genetic aberrations in exfoliated cells in the urine, with specific 
      probes for chromosomes 3, 7 and 17 and the p16 gene. To evaluate the diagnostic 
      value of FISH in UC, 119 patients from November 2010 to June 2012 with suspected 
      UC were recruited into a prospective, cross-sectional study and were followed up 
      for 12-30 months. These patients received voided urine cytology and FISH tests, 
      and underwent cystoscopy and/or ureteroscopy as a reference standard. The final 
      diagnoses confirmed 73 patients with UC, located in the bladder, upper urinary 
      tracts or the two. The sensitivity of FISH for detecting UC was superior to 
      cytology, irrespective of tumor grade and stage: Overall, 80.8 vs. 32.9% 
      (P<0.001); low grade, 75.8 vs. 12.1% (P<0.001); high grade, 85 vs. 50% (P<0.005); 
      non-muscle-invasive, 81.1 vs. 28.3% (P<0.001) and muscle-invasive, 80 vs. 45% 
      (P<0.05), respectively. The specificities of the two tests were similar; overall, 
      the specificity was 89.1% for cytology vs. 100% for FISH, and no significant 
      difference was observed between the methods. Notably, FISH exhibited 100% 
      sensitivity for cytologically non-diagnostic UC, but 33.3% specificity. In 
      conclusion, FISH is a reliable and non-invasive diagnostic tool for bladder and 
      upper urinary tract UC, particularly in patients with low-grade or early stage 
      tumors.
FAU - Lin, Tianhai
AU  - Lin T
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
AD  - Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
AD  - Department of Translational Molecular Pathology, University of Texas M.D. Cancer 
      Center, Houston, TX 77030, USA.
FAU - Liu, Zhenhua
AU  - Liu Z
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
AD  - Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
FAU - Liu, Liangren
AU  - Liu L
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
AD  - Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
FAU - Yang, Lu
AU  - Yang L
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
AD  - Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
FAU - Han, Ping
AU  - Han P
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
AD  - Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
AD  - Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
FAU - Wei, Qiang
AU  - Wei Q
AD  - Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
AD  - Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 
      610041, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170327
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5431676
OTO - NOTNLM
OT  - bladder cancer
OT  - cytology
OT  - diagnosis
OT  - fluorescence in situ hybridization
OT  - sensitivity
OT  - specificity
OT  - transitional cell carcinoma
OT  - urothelial carcinoma
EDAT- 2017/05/23 06:00
MHDA- 2017/05/23 06:01
PMCR- 2017/03/27
CRDT- 2017/05/23 06:00
PHST- 2016/03/14 00:00 [received]
PHST- 2017/01/31 00:00 [accepted]
PHST- 2017/05/23 06:00 [entrez]
PHST- 2017/05/23 06:00 [pubmed]
PHST- 2017/05/23 06:01 [medline]
PHST- 2017/03/27 00:00 [pmc-release]
AID - OL-0-0-5926 [pii]
AID - 10.3892/ol.2017.5926 [doi]
PST - ppublish
SO  - Oncol Lett. 2017 May;13(5):3928-3934. doi: 10.3892/ol.2017.5926. Epub 2017 Mar 
      27.